GSK closes $10.6B Nuvalent buyout; shares head for delisting

summarizeSummary

GSK completed its $10.6 billion acquisition of Nuvalent on July 15, 2026, after 91.3% of shares were tendered. The merger closed and Nuvalent's stock is being delisted from Nasdaq.

check_boxKey Events · M&A and Partnerships · NUVL

• Merger Completed

  Closing on July 15, 2026, the acquisition was effected through a short-form merger under Section 251(h), bypassing a stockholder vote. Nuvalent is now a wholly owned GSK subsidiary.

• Tender Offer Results

  By the July 14 expiration, 91.3% of outstanding shares—72.5 million in total—had been validly tendered, clearing the minimum condition. GSK accepted all tendered shares for payment at $124.00 per share.

• Delisting and Deregistration

  Nasdaq has been notified to halt trading and file Form 25 to delist the Class A common stock. The company will also file Form 15 to suspend its SEC reporting obligations.

• Board and Management Overhaul

  All eight pre-merger directors resigned, making way for two GSK-appointed directors. The incumbent officers were replaced by GSK personnel, with Justin Huang assuming the roles of President and Secretary.

auto_awesomeAnalysis · NUVL · Life Sciences

The $10.6 billion all-cash acquisition of Nuvalent by GSK closed today, marking the final chapter of a process that kicked off with the June 9 merger agreement. With 91.3% of shares validly tendered by the July 14 expiration, the minimum condition was comfortably met, allowing the merger to be completed without a stockholder vote under Delaware's Section 251(h). Nuvalent now operates as a wholly owned GSK subsidiary, its Nasdaq listing is being terminated, and the entire pre-merger board and management team have stepped aside for GSK appointees.